Skip to content

Clinical and laboratory evaluation of Laser in the treatment of Periodontal Disease

Clinical and microbiological evaluation of Laser Therapy in the treatment of stage III and IV Periodontal Disease patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-10n8d52v
Enrollment
Unknown
Registered
2025-09-10
Start date
2024-05-07
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Interventions

This is a split-mouth, triple-blind, randomized controlled clinical study. Participants will have their periodontal clinical parameters (plaque index, gingival index, probing depth, gingival recession
Red laser photobiomodulation (PBMV): Photobiomodulation will be performed with a red laser (660 nm) in 20 sites using a Duo? laser with the optical fiber inside the periodontal pocket in back and fort
Photobiomodulation with infrared laser (PBMIV): Photobiomodulation will be performed with an infrared laser (808 nm) in 20 sites using a Duo? laser with the optical fiber inside the periodontal pocket

Sponsors

Universidade Federal Fluminense - Polo de Nova Friburgo
Lead Sponsor
Universidade Federal Fluminense - Polo de Nova Friburgo
Collaborator

Eligibility

Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers; both genders; aged between 18 and 70 years; with four or more periodontal sites with probing depth greater than or equal to 6 millimeters and clinical attachment level grater then or equal to 5 millimeters non-adjacent

Exclusion criteria

Exclusion criteria: Hypersensitivity to the components of 0.005 percent methylene blue gel; patients who received periodontal treatment in the last six months; use of medications as anti-inflammatories and antibiotics in the last 3 months; any evidence of systemic modifying factors that may directly interfere as bias, such as: pregnant and breastfeeding women, on hormone replacement therapy, smokers, diagnosed with hyperglycemia and diabetes, osteoporosis; with HIV+ or AIDS

Design outcomes

Primary

MeasureTime frame
To evaluate the impact of different treatments on the periodontal clinical parameter probing depth, given in millimeters, measured at the initial time and after 3 months of treatment, using the periodontal probing method with the use of a PCP15UNC periodontal probe (Hu-Friedy, Chicago, IL , USA).;To evaluate the impact of different treatments on the periodontal clinical parameter clinical level of attachment, given in millimeters, measured at the initial time and after 3 months of treatment, using the periodontal probing method using a PCP15UNC periodontal probe (Hu-Friedy, Chicago, IL, USA).

Secondary

MeasureTime frame
To evaluate the presence of periodontal pathogens in biofilms in the gingival fluid of four sites with probing depth =6 mm before and after treatments. Samples will be collected at selected locations and stored in eppendorfs with 1X PBS at -20oC and evaluated using DNA extraction, electrophoresis and qualitative polymerase chain reaction (PCR) methods.;To evaluate the periodontal clinical parameter plaque index, given as a percentage, measured at the initial time and after 3 months of treatment, using the method described by Ainamo and Bay (1975).;Evaluate the periodontal clinical parameter gingival index, given in percentage, measured at the initial time and after 3 months of treatment, using the method described by Ainamo and Bay (1975).;To evaluate the periodontal clinical parameter gingival recession, given in millimeters, measured at the initial time and after 3 months of treatment, using the periodontal probing method using a PCP15UNC periodontal probe (Hu-Friedy, Chicago, IL, USA).

Countries

Brazil

Contacts

Public ContactRaquel Carmo

Universidade Federal Fluminense

carmoalvesraquel@gmail.com+55(22)99913-7732

Outcome results

None listed

Source: REBEC (via WHO ICTRP)